Skip to main content
Signal8
Launch Terminal

Bioventus Inc. (BVS)

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Bioventus Inc. logo

Bioventus Inc.

NASDAQ:BVSHealthcare
-10.39%$13.32
AH$13.32-0.04%vs close
Mkt Cap$910.17M
Float45.78M
O/S68.31M
Vol
$ Vol
RVOL
Inst Own78.9%
SI6.9%
Earnings
Dilution
Bioventus Inc. logoNASDAQ:BVS$13.32-10.39%
Phase Distribution
14 lead-sponsored trials·1 active·7 completed
Phase 11
Phase 21
Phase 41
Not applicable11
(3 more as collaborator)
Status Overview
Active, not recruiting1
Completed7
Stopped3
Unknown3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Unknown status

    26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle

    Durolane SJ

    Osteoarthritis

    Enrollment
    37
    Start
    Jun 2014
    Primary Completion
    Aug 2016
    Completion
    Oct 2016est.
    NCT02627859
  • Phase 2
    Active, not recruiting

    Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

    PTP-001

    Osteoarthritis, Knee

    Enrollment
    210
    Start
    Sep 2021
    Primary Completion
    Oct 2022est.
    Completion
    Nov 2022est.
    NCT05100225
  • Phase 1
    Unknown status

    Safety Study of PTP-001 for Treating Knee Osteoarthritis

    Biological: PTP-001

    Knee Osteoarthritis

    Enrollment
    20
    Start
    Feb 2021
    Primary Completion
    Sep 2022est.
    Completion
    Dec 2022est.
    NCT04632966
  • Not applicable
    Completed

    SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder

    SUPARTZ®, Phosphate Buffered Saline

    Osteoarthritis of the Shoulder

    Enrollment
    300
    Start
    May 2007
    Primary Completion
    Oct 2009
    Completion
    Oct 2009
    NCT00479687
  • Not applicable
    Terminated

    Trial to Evaluate UltraSound in the Treatment of Tibial Fractures

    Exogen 4000+, Sham

    Tibial Fractures

    Enrollment
    501
    Start
    Sep 2008
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT00667849
  • Not applicable
    Terminated

    Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery

    Exospine sham, Exospine

    Lumbar Degenerative Disc Disease

    Enrollment
    328
    Start
    Sep 2008
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT00744861
  • Not applicable
    Completed

    Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain

    ARTZ, DUROLANE

    Knee Osteoarthritis

    Enrollment
    349
    Start
    Jan 2011
    Primary Completion
    Aug 2011
    Completion
    Feb 2012
    NCT01295580
  • Not applicable
    Terminated

    Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee

    3ml hyaluronic acid (DUROLANE), 2ml hyaluronic acid, (HYALGAN)

    Knee Osteoarthritis

    Enrollment
    290
    Start
    Feb 2012
    Primary Completion
    Feb 2014
    Completion
    Feb 2014
    NCT01543737
  • Not applicable
    Completed

    Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA

    Supartz, Euflexxa

    Osteoarthritis

    Enrollment
    421
    Start
    Mar 2014
    Primary Completion
    Nov 2014
    Completion
    Feb 2015
    NCT02110238
  • Observational
    Completed

    A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®

    OsteoAMP

    Spondylolisthesis, Scoliosis +1

    Enrollment
    42
    Start
    Nov 2015
    Primary Completion
    Jun 2019
    Completion
    Oct 2019
    NCT02225444
  • Not applicable
    Completed

    Prospective Single Center Open Label Study of Shoulder OA Pain

    Durolane

    Osteoarthritis

    Enrollment
    41
    Start
    Apr 2015
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT02610504
  • Observational
    Completed

    Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at Risk

    Low intensity pulsed ultrasound

    Mitigation of Fracture Non-union in Patients at Risk

    Enrollment
    12,387
    Start
    Oct 2017
    Primary Completion
    May 2020
    Completion
    May 2022
    NCT03382483
  • Not applicable
    Unknown status

    OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study

    OSTEOAMP, Infuse

    Lumbar Spine Disease, Lumbar Spondylolisthesis +3

    Enrollment
    101
    Start
    May 2022
    Primary Completion
    Oct 2024est.
    Completion
    Oct 2025est.
    NCT05405374
  • Observational
    Completed

    Study of StimRouter for Chronic Knee OA Pain

    StimRouter Neuromodulation System

    Osteoarthritis, Knee

    Enrollment
    13
    Start
    Oct 2022
    Primary Completion
    Oct 2023
    Completion
    Jun 2024
    NCT05644639
Search ClinicalTrials.gov for “Bioventus”